PNPLA3 and metabolic dysfunction-associated steatotic liver disease: A multi-center cohort study on NAFLD patients showed that the protective effect of statin therapy, as a means to inhibit cholesterol synthesis, on steatohepatitis was significantly lower in the carriers of the PNPLA3 risk variant.